熱門資訊> 正文
ViiV的Dovato在正面试验中与Gilead的Biktavy一样有效
2026-07-28 01:44
- ViiV Healthcare, which is majority owned by GSK (GSK), said that a head-to-head study of its HIV treatment Dovato (dolutegravir/lamivudine), which contains two drugs, is as effective as Gilead Sciences' (GILD) three-drug Biktarvy (bictegravir/emtricitabine/tenofovir).
- Results from the phase 3b open-label VOGUE study that enrolled around 500 treatment-naive patients with HIV found that at 48 weeks, virologic suppression was 89% in the Dovato group and 92% in the Biktarvy cohort.
- Median time to viral suppression was the same in both groups -- about 4.1 weeks.
More on GSK
- GSK: Buy The Discount Before The Catalysts Close It
- Is GSK Quietly Becoming An Oncology Powerhouse?
- Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors
- GSK Earnings Preview: EPS to take a plunge; CEO's comments, guidance in focus
- U.S. measles cases exceed 2025 total to reach highest in 35 years
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
